about
Biochemical Markers of Physical Exercise on Mild Cognitive Impairment and Dementia: Systematic Review and PerspectivesCerebrospinal Fluid Biomarkers in Familial Forms of Alzheimer's Disease and Frontotemporal DementiaProteomic investigations of the ventriculo-lumbar gradient in human CSF.Identification of CSF biomarkers for frontotemporal dementia using SELDI-TOF.Cystatin C in cerebrospinal fluid and multiple sclerosis.Amyloid beta1-40 quantification in CSF: comparison between chromatographic and immunochemical methods.Novel panel of cerebrospinal fluid biomarkers for the prediction of progression to Alzheimer dementia in patients with mild cognitive impairment.A novel panel of cerebrospinal fluid biomarkers for the differential diagnosis of Alzheimer's disease versus normal aging and frontotemporal dementia.Three new potential ovarian cancer biomarkers detected in human urine with equalizer bead technology.Sample handling for mass spectrometric proteomic investigations of human urine.Protein profiling of cerebrospinal fluid.Protein markers for the differential diagnosis of vascular dementia and Alzheimer's disease.Pre-analytical factors influencing the stability of cerebrospinal fluid proteins.Ubiquitin: a potential cerebrospinal fluid progression marker in Huntington's disease.The Central Biobank and Virtual Biobank of BIOMARKAPD: A Resource for Studies on Neurodegenerative Diseases.The PredictAD project: development of novel biomarkers and analysis software for early diagnosis of the Alzheimer's diseaseAre CSF Biomarkers Useful as Prognostic Indicators in Diagnostically Unresolved Cognitively Impaired Patients in a Normal Clinical SettingDistinct transthyretin oxidation isoform profile in spinal fluid from patients with Alzheimer's disease and mild cognitive impairmentRecommendations to standardize preanalytical confounding factors in Alzheimer's and Parkinson's disease cerebrospinal fluid biomarkers: an update.The potential of microRNAs as biofluid markers of neurodegenerative diseases--a systematic review.The utility of α-synuclein as biofluid marker in neurodegenerative diseases: a systematic review of the literature.Chasing the Effects of Pre-Analytical Confounders - A Multicenter Study on CSF-AD Biomarkers.Effect of physical exercise on markers of neuronal dysfunction in cerebrospinal fluid in patients with Alzheimer's disease.Neprilysin-like activity correlates with CSF-Tau and phospho-tau in patients with Alzheimer's disease.YKL-40 in cerebrospinal fluid in Huntington's disease--a role in pathology or a nonspecific response to inflammation?Application of the PredictAD decision support tool to a Danish cohort of patients with Alzheimer's disease and other dementias.Cerebrospinal Fluid Amyloid Beta and Tau Concentrations Are Not Modulated by 16 Weeks of Moderate- to High-Intensity Physical Exercise in Patients with Alzheimer Disease.Does Caffeine Consumption Modify Cerebrospinal Fluid Amyloid-β Levels in Patients with Alzheimer's Disease?CSF neurofilament light concentration is increased in presymptomatic CHMP2B mutation carriers.A Parallel Reaction Monitoring Mass Spectrometric Method for Analysis of Potential CSF Biomarkers for Alzheimer's Disease.Recommendations for cerebrospinal fluid Alzheimer's disease biomarkers in the diagnostic evaluation of mild cognitive impairment.Recommendations for CSF AD biomarkers in the diagnostic evaluation of dementia.Preserving cognition, quality of life, physical health and functional ability in Alzheimer's disease: the effect of physical exercise (ADEX trial): rationale and design.The Diagnostic and Prognostic Value of a Dual-Tasking Paradigm in a Memory Clinic.Measurement of 8-oxo-7,8-dihydro-2'-deoxyguanosine and 8-oxo-7,8-dihydro-guanosine in cerebrospinal fluid by ultra performance liquid chromatography-tandem mass spectrometry.Application of the PredictAD software tool to predict progression in patients with mild cognitive impairment.A disease state fingerprint for evaluation of Alzheimer's disease.Characterization and stability of transthyretin isoforms in cerebrospinal fluid examined by immunoprecipitation and high-resolution mass spectrometry of intact protein.Identification of a novel panel of cerebrospinal fluid biomarkers for Alzheimer's disease.Biomarkers in cerebrospinal fluid of patients with bipolar disorder versus healthy individuals: A systematic review
P50
Q26784555-B3814897-9A65-4DDC-8B11-8CD8F4F9384EQ28082814-49C645F1-1A03-4AB5-861F-583AE0C9FF9CQ30985215-8921E470-1D5F-4739-A0E2-8592DE68A899Q33223096-302D48AF-9905-4D6F-AA3F-5F132EC6A254Q33253507-C543DBEB-1103-498C-AB01-31AAF4B2EC34Q33274612-8670C0C4-EB05-4E81-93D2-BE2F6E791A85Q33278028-B5918756-7B56-4611-8FB8-705DD71511D9Q33304417-94F4B146-E50C-4ADC-90E1-AAD4928ECC13Q33386060-5C21DA9F-4F18-423F-B1C1-93E873FD60F8Q33764413-E7B44DC2-8848-4278-AEAC-7198A72A59ADQ34074472-BCCCB8AF-4BB2-4A5B-913D-5EB4FFC6B4F8Q34305901-B3D9C2F6-5E29-4CC4-BADF-CF7F9756ADF6Q34641130-F4A12DD9-574D-4158-9F74-566E536BFC22Q35663352-EE0C7A4E-2ACE-4BFB-AFBB-BB9BED670641Q36162523-3A71A775-075F-46DE-9F18-87E4E4FBD1BDQ36801446-35C95043-9C49-40B2-BE85-616D7CD527DDQ37387826-73AF24B0-BF41-40EC-89B3-736D69200973Q37680840-272A1307-3CFF-4BC7-A77C-B2F24B7E2D53Q38037155-655E3DC2-E290-43C3-93E1-8FE7AED44BA9Q38200138-DFAE0639-263E-4E6C-B7A2-F9243C8470C2Q38575114-0863EA23-31D0-4B54-AED1-14290E0F0CC3Q41245550-4BCCAEB4-B34D-4C23-90BA-02EE99CBE2D0Q42655670-4F65A8EA-835B-4460-BE05-073D98672A3BQ44769024-9B1FF4FA-0111-4495-A02A-FE8427DA971FQ45301711-159D637A-40C7-40D9-85CE-CE7CDE608193Q45717852-1BFA93A8-A227-44FD-B1E0-A99A65413D82Q46468277-9FB174E2-D10C-43E1-B24F-D5B759F05471Q46664880-4CB165EA-E4D8-4F00-A269-50025CEF1A2FQ47315423-C7914D97-C522-4D7E-8233-4C37AD5DB0C5Q47658065-55046D83-2A47-41E2-84E0-7E511F3FAF74Q47767141-EC047DEB-70A2-40C3-92CB-F7BEE0EFFFBFQ47767152-AAA6534A-CB36-4E37-987E-A692916F7AB9Q48150029-93A5427A-430D-45FB-8780-247B6FE6C43BQ49571127-0EDA1C42-C7B9-40B6-A22E-F56F663DCC98Q49720394-EE4DC499-3F69-42F4-ACAD-B406029B249FQ50925219-9BE46E77-2AAC-4509-840D-FE448852CBDFQ51544152-D6BFCCA0-7283-4C05-83E7-82E723950EFBQ53325805-859D24A9-A60F-4C68-A153-E4B4B4A187FEQ53384974-FD4496B6-18B9-4D23-90D1-F0EE7F5A1F63Q57178040-CFE36834-B2C7-4F29-B25D-070F0352EDA7
P50
description
Deens onderzoekster
@nl
dansk forsker
@nb
hulumtuese
@sq
researcher
@en
հետազոտող
@hy
name
Anja H Simonsen
@ast
Anja H Simonsen
@es
Anja H Simonsen
@nl
Anja H Simonsen
@sl
Anja H. Simonsen
@da
Anja H. Simonsen
@de
Anja H. Simonsen
@en
Anja H. Simonsen
@fr
Anja H. Simonsen
@nb
Anja H. Simonsen
@nn
type
label
Anja H Simonsen
@ast
Anja H Simonsen
@es
Anja H Simonsen
@nl
Anja H Simonsen
@sl
Anja H. Simonsen
@da
Anja H. Simonsen
@de
Anja H. Simonsen
@en
Anja H. Simonsen
@fr
Anja H. Simonsen
@nb
Anja H. Simonsen
@nn
altLabel
Anja Hviid Simonsen
@en
Anja Simonsen
@en
prefLabel
Anja H Simonsen
@ast
Anja H Simonsen
@es
Anja H Simonsen
@nl
Anja H Simonsen
@sl
Anja H. Simonsen
@da
Anja H. Simonsen
@de
Anja H. Simonsen
@en
Anja H. Simonsen
@fr
Anja H. Simonsen
@nb
Anja H. Simonsen
@nn
P106
P21
P27
P31
P496
0000-0002-5461-162X